TNXP (Tonix Pharmaceuticals Holding) Margin of Safety % (DCF FCF Based) : N/A (As of Apr. 05, 2025)

View and export this data going back to 2009. Start your Free Trial

What is Tonix Pharmaceuticals Holding Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Tonix Pharmaceuticals Holding's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Tonix Pharmaceuticals Holding's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tonix Pharmaceuticals Holding's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Tonix Pharmaceuticals Holding's Margin of Safety % (DCF FCF Based) falls into.

Save Embed

;

Save Embed

;

Tonix Pharmaceuticals Holding Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Tonix Pharmaceuticals Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (NAS:TNXP) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

26 Main Street, Suite 101, Chatham, NJ, USA, 07928

Website

https://www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Executives

Richard Newcomb Stillwell	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Seth Lederman	director, 10 percent owner, officer: Chief Executive Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Carolyn E. Taylor	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Daniel Wintner Goodman	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE, NEW YORK NY 10022
James Treco	director	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., NEW YORK NY 10022
Margaret Smith Bell	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Gregory M Sullivan	officer: Chief Medical Officer	C/O TONIX PHARMACEUTICALS HOLDINGS CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Richard H Bagger	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE. - SUITE 1608, NEW YORK NY 10022
Adeoye Y Olukotun	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
David L Grange	director
Ernest Mario	director	20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Jessica Edgar Morris	officer: Chief Administrative Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Bradley Saenger	officer: Chief Financial Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
John B Rhodes	director	74 FIFTH AVENUE, NEW YORK NY 10011
Samuel R Saks	director	3180 PORTER DRIVE, PALO ALTO CA 94304